

TRINITY BIOTECH PLC
Form SC 13G/A
February 15, 2018

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 4) *

Trinity Biotech plc
(Name of Issuer)

American Depositary Shares
(Title of Class of Securities)

896438306
(CUSIP Number)

02/09/2018
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:

☒ Rule 13d-1(b)
☐ Rule 13d-1(c)
☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting
persons initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be filed for the purpose of Section 18 of the Securities Exchange
Act of 1934 (Act) or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

CUSIP No. 896438306

1. Names of Reporting Persons.
Lapides Asset Management, LLC
13-4300774

2. Check the Appropriate Box if a Member of a Group
Not Applicable

3. SEC Use Only

4. Citizenship or Place of Organization
Connecticut

Number of Shares
Beneficially
Owned by
Each Reporting
Person With:

5. Sole Voting Power

Edgar Filing: TRINITY BIOTECH PLC - Form SC 13G/A

923,200

6. Shared Voting Power
none

7. Sole Dispositive Power
1,211,900

8. Shared Dispositive Power
None

9. Aggregate Amount Beneficially Owned by Each Reporting Person
1,211,900

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
Not Applicable

11. Percent of Class Represented by Amount in Row (9)
5.0%

12. Type of Reporting Person (See Instructions)
IA

CUSIP No. 896438306

ITEM 1.

(a) Name of Issuer: Trinity Biotech plc

(b) Address of Issuer's Principal Executive Offices:
IDA Business Park
Bray, Co
Wicklow, Ireland L2 18

ITEM 2.

(a) Name of Person Filing: Lapidex Asset Management, LLC ("Lapidex")

(b) Address of Principal Business Office, or if None, Residence:
500 W. Putnam Avenue
4th Floor
Greenwich, CT 06830

(c) Citizenship:
Lapidex is a Connecticut limited liability company

(d) Title of Class of Securities: American Depositary Shares

(e) CUSIP Number: 896438306

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

(e) ☒ [X] An investment adviser in accordance with ss.240.13d-1(b) (1) (ii) (E)

ITEM 4. OWNERSHIP.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned: See Item 9 of Cover Pages

(b) Percent of class: see Item 11 of Cover Pages

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote
See Item 5 of Cover Pages.

(ii) Shared power to vote or to direct the vote
See Item 6 of Cover Pages.

Edgar Filing: TRINITY BIOTECH PLC - Form SC 13G/A

- (iii) Sole power to dispose or to direct the disposition of
See Item 7 of Cover Pages.
- (iv) Shared power to dispose or to direct the disposition of
See Item 8 of Cover Pages.

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
Not Applicable

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Funds managed on a discretionary basis by Lapides Asset Management are known to have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sales of such securities. None of the partners or funds beneficially own more than 5% of the stock.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
Not applicable

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable

ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not Applicable

ITEM 10. CERTIFICATION.
(a) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(b):

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

(b) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(c):

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 15, 2018

(Date)

James F. Betz

(Signature)

James F. Betz, Chief Operating Officer

(Name/Title)

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an

Edgar Filing: TRINITY BIOTECH PLC - Form SC 13G/A

executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7 for other parties for whom copies are to be sent.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)